Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer

Scandinavian Journal of Urology and Nephrology

Volumn 45, Issue 2, 2011, Pages 113-121

  Kehinde, Elijah O ^a   Al Mulla, Fahd ^a   Kapila, Kusum ^a   Anim, Jehoram T ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Bladder cancer; diagnosis; NMP22; urine cytology; UroVysion FISH

Indexed keywords

NUCLEAR MATRIX PROTEIN 22;

ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER REGRESSION; CONTROLLED STUDY; CYSTOSCOPY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINE CULTURE; URINE CYTOLOGY;

ADOLESCENT; ADULT; AGED; BIOPSY; CASE-CONTROL STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINALYSIS; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 79951828764     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.3109/00365599.2010.533694     Document Type: Article

References (22)

1. Murphy W. Current status of urinary cytology in evaluation of bladder neoplasms. Hum Pathol 1990;21:886-96. (Pubitemid 20308410)
2. Raitanen MP, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, et al. FinnBladder Group. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002;41:284-9. (Pubitemid 35303426)
3. Sarosdy MF, Kahn PR, Ziffer MD, Love WR, Barkin J, Abara EO, et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with haematuria. J Urol 2006;176:44-7. (Pubitemid 43833178)
4. Schmitz-Drager BJ, Beiche B, Tirsar LA, Schmitz-Drager C, Bismarck E, Ebert T. Immunocytology in the assessment of patients with asymptomatic microhaematuria. Eur Urol 2007;51:1582-8. (Pubitemid 46656312)
5. Bott S, Chanawani M, Mostafid H. The use of the NMP22 bladdercheck test for bladder cancer to optimize investigations in a one-stop haematuria clinic. Br J Med Sci Surg Urol 2008;1:126-30.
6. McNeil BK, Getzenberg RH. Urine-based markers in bladder cancer: future prospects BJU Int 2008;101:668-9. (Pubitemid 351270009)
7. Agarwal PK, Black PC, Kamat AM. Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol 2008;26:39-44.
8. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP III, et al. Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. Urology 2005;66:35-63. (Pubitemid 43049608)
9. Papanicolaou GN, Marshall VF. Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 1945;101:519-20.
10. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systemic review. Eur Urol 2005;47:736-48. (Pubitemid 40745338)
11. Miyanaga N, Akaza H, Tsukamoto S, Shimazui T, Ohtani M, Ishikawa S, et al. Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection. Int J Clin Oncol 2003;8: 369-73. (Pubitemid 38036093)
12. Boman H, Hedelin H, Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 2002;167:80-3. (Pubitemid 34024504)
13. Nielsen ME, Schaffer EM, Veltri RW, Schoenberg MP, Getzenberg RH. Urinary markers in the detection of bladder cancer: what's new? Curr Opin Urol 2006;16: 350-5. (Pubitemid 44231711)
14. Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urol Oncol 2006;24:326-37. (Pubitemid 43963409)
15. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999;162: 53-7e.
16. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006; 295:299-305. (Pubitemid 43112958)
17. Witjes JA, van der Poel HG, van Balken MR, Debruyne FMJ, Schalken JA. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur Urol 1998;33:387-91. (Pubitemid 28230263)
18. Lokeshwar VB, Selzer MG. Urinary bladder tumor markers. Urol Oncol 2006;24:528-37. (Pubitemid 44810015)
19. Horstmann M, Patschan O, Hennenlotter J, Senger E, Feil G, Stenzl A. Combinations of urine based tumour markers in bladder cancer surveillance. Scand J Urol Nephrol 2009;43:461-6.
20. Villicana P, Whiting B, Goodison S, Rosser CJ. Urine based assays for the detection of bladder cancer. Biomark Med 2009;3:265-70.
21. Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int 2008;102: 1111-14.
22. Lotan Y, Shariat SF, NMP22 Study Group. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. BJU Int 2008;101:1362-7. (Pubitemid 351623980)